Beijing Qihui Biopharmaceuticals Co., Ltd reportedly raised “tens of millions” of renminbi in a Series A financing round led by Wedo Capital, with contributions from Qingdao Conson Financial Holdings. Proceeds will go towards phospholipid-coated microbubbles technology platform construction, phospholipid-coated microbubbles ultrasound contrast pipeline development, and industrialization.
Company Background and Technology
Founded in 2016, Qihui Bio has developed multiple contrast products based on its core delivery technology and manufacturing technology.-Fineline Info & Tech
